Search results for "ANTIBODIES"

showing 10 items of 1885 documents

Novel anti-GARP antibody DS-1055a augments anti-tumor immunity by depleting highly suppressive GARP+ regulatory T cells

2021

Abstract Regulatory T (Treg) cells, which are essential for maintaining self-tolerance, inhibit anti-tumor immunity, consequently hindering protective cancer immunosurveillance, and hampering effective anti-tumor immune responses in tumor-bearing hosts. Here, we show that depletion of Treg cells via targeting glycoprotein A repetitions predominant (GARP) induces effective anti-tumor immune responses. GARP was specifically expressed by highly suppressive Treg cells in the tumor microenvironment (TME) of multiple cancer types in humans. In the periphery, GARP was selectively induced in Treg cells, but not in effector T cells, by polyclonal stimulation. DS-1055a, a novel afucosylated anti-huma…

0301 basic medicinemedicine.drug_classmedicine.medical_treatmentImmunologychemical and pharmacologic phenomenaMice SCIDBiologyMonoclonal antibodyT-Lymphocytes RegulatoryMice03 medical and health sciences0302 clinical medicineImmune systemCancer immunotherapyMice Inbred NODImmunityNeoplasmsImmune ToleranceTumor MicroenvironmentmedicineAnimalsHumansImmunology and AllergyMice KnockoutTumor microenvironmentImmunityAntibodies MonoclonalMembrane ProteinsFOXP3General MedicineImmunosurveillance030104 developmental biology030220 oncology & carcinogenesisLeukocytes MononuclearCancer researchbiology.proteinFemaleImmunotherapyAntibodyInternational Immunology
researchProduct

Inactivation of the KSRP gene modifies collagen antibody induced arthritis.

2017

Abstract The KH type splicing regulatory protein (KSRP) is a nucleic acid binding protein, which negatively regulates the stability and/or translatability of many mRNA species encoding immune-relevant proteins. As KSRP is expressed in immune cells including T and B cells, neutrophils, macrophages and dendritic cells, we wanted to analyze its importance for the development of autoimmune diseases. We chose collagen antibody-induced arthritis (CAIA) as an appropriate autoimmune disease mouse model in which neutrophils and macrophages constitute the main effector cell populations. We compared arthritis induction in wild type (WT) and KSRP−/− mice and paws were taken for histological sections an…

0301 basic medicinemedicine.drug_classmedicine.medical_treatmentInflammatory arthritisChemokine CXCL1ImmunologyArthritisAntigens Differentiation MyelomonocyticNitric Oxide Synthase Type IISpleenBiologyMonoclonal antibodyPeripheral blood mononuclear cellAntibodiesFlow cytometry03 medical and health sciencesInterferon-gammaMiceImmune systemAntigens CDmedicineAnimalsAntigens LyCalgranulin ARNA MessengerMolecular BiologyInflammationmedicine.diagnostic_testTumor Necrosis Factor-alphaMacrophagesRNA-Binding Proteinsmedicine.diseaseMolecular biologyArthritis ExperimentalLymphocyte Function-Associated Antigen-1Mice Inbred C57BL030104 developmental biologyCytokinemedicine.anatomical_structureImmunologyTrans-ActivatorsCytokinesCollagenMolecular immunology
researchProduct

Adherence to dietary treatment and clinical factors associated with anti-transglutaminase antibodies in celiac disease during the follow-up

2021

Introduction In clinical practice, celiac disease (CD) is monitored through anti-transglutaminase (TGA-IgA) antibody levels. The normalization of serum levels in successive periodic measurements indicates good response and adherence to dietary treatment. Objectives To evaluate the factors associated with the evolution of TGA-IgA antibodies and their association with dietary non-compliance and diseases related to CD. Methods This prospective observational study was carried out in 254 participants, who were recruited from patients from a hospital in southern Spain. Information about sex, age, serological test results, HLA DQ2/DQ8 haplotypes, mucosal atrophy, gastrointestinal and extra-intesti…

0301 basic medicinemedicine.medical_specialtyAbdominal painScience (General)PopulationDiseaseSerology03 medical and health sciencesQ1-3900302 clinical medicineAtrophyWeight lossInternal medicinemedicineTGA-IgA antibodiesCeliac diseaseeducationH1-99education.field_of_studyMultidisciplinarybiologybusiness.industryHLA-DQ2medicine.diseaseDietSocial sciences (General)030104 developmental biologyDietary non-complianceAnti-transglutaminase antibodiesbiology.proteinmedicine.symptombusiness030217 neurology & neurosurgeryResearch ArticleHeliyon
researchProduct

Alzheimer's disease: Only prevention makes sense

2018

Alzheimer's disease therapeutics is one of the most important endeavours in today's clinical investigation. Over more than 30 years of research, no disease-modifying treatment has been approved by either the FDA or the EMA to treat Alzheimer's disease. Recently, the evidence of pathological alterations in the brain tissue has been gathered showing that the signs of brain damage appear more than 20 years before the onset of Alzheimer's dementia. The major aim of this review is to underpin the idea that in Alzheimer's therapeutics, only prevention makes sense. It is difficult to visualise that would-be patients may be treated with endovenous administration of antibodies for several years to d…

0301 basic medicinemedicine.medical_specialtyClinical BiochemistryBrain damageDiseaseBiochemistryAsymptomaticAntioxidantsMice03 medical and health sciences0302 clinical medicineAlzheimer DiseaseAnimalsHumansVitamin EMedicineDementiaHealthy LifestyleTreatment FailureIntensive care medicinePathologicalNootropic AgentsAgedAged 80 and overClinical Trials as Topicbusiness.industryAntibodies MonoclonalCognitionGeneral MedicineMiddle Agedmedicine.diseaseClinical trialDisease Models Animal030104 developmental biologymedicine.symptombusiness030217 neurology & neurosurgeryMinimal cognitive impairmentEuropean Journal of Clinical Investigation
researchProduct

IL-1β at the crossroad between rheumatoid arthritis and type 2 diabetes: may we kill two birds with one stone?

2016

ABSTRACT: Although in the past the prevention of joint destruction in rheumatoid arthritis (RA) was strongly emphasized, now a great interest is focused on associated comorbidities in these patients. Multiple data suggest that a large percentage of RA patients are affected by Type 2 Diabetes (T2D), whose incidence has reached epidemic levels in recent years, thus increasing the health care costs. A better knowledge about the pathogenesis of these diseases as well as the mechanisms of action of drugs may allow both policy designers and physicians to choose the most effective treatments, thus lowering the costs. This review will focus on the role of Interleukin (IL)-1β in the pathogenesis of …

0301 basic medicinemedicine.medical_specialtyIL-1 blocking agentpathogenesimedicine.medical_treatmentInterleukin-1betaImmunologyType 2 diabetesComorbiditymacrophagePathogenesisArthritis Rheumatoid03 medical and health sciencesHealth careMedicineAnimalsHumansImmunology and AllergyRheumatoid arthritisIntensive care medicineAntibodies BlockingRheumatoid arthrititype 2 diabetebusiness.industryIL-1 blocking agentsIncidence (epidemiology)pathogenesisInterleukinImmunotherapybiologic drug; IL-1 blocking agents; IL-1β; macrophage; pathogenesis; Rheumatoid arthritis; type 2 diabetes; Immunology and Allergy; Immunologymedicine.diseaseComorbiditySettore MED/16 - Reumatologia030104 developmental biologyDiabetes Mellitus Type 2IL-1βRheumatoid arthritisImmunologyImmunotherapytype 2 diabetesbusinessbiologic drug
researchProduct

Olaratumab: PDGFR-α inhibition as a novel tool in the treatment of advanced soft tissue sarcomas

2017

Advanced soft tissue sarcomas are aggressive cancers with limited therapeutic options. Recently, inhibition of platelet-derived growth factor receptor (PDGFR)-α by the monoclonal antibody olaratumab showed promising clinical activity. If confirmed, this would be one of the first examples of targeted therapy effective in advanced soft tissue sarcomas therapy independently of the histologic subtype. Here, we reviewed the biology of the PDGF/PDGFR axis, particularly focusing on its role in cancer, and then we discussed on the effects of PDGFR-α inhibition in the therapy of advanced soft tissue sarcomas.

0301 basic medicinemedicine.medical_specialtyPathologyReceptor Platelet-Derived Growth Factor alphamedicine.medical_treatmentPDGFR-αAntineoplastic AgentsTargeted therapy03 medical and health sciences0302 clinical medicineGrowth factor receptorDoxorubicin; Olaratumab; PDGFR-α; Soft tissue sarcomas; Hematology; Oncology; Geriatrics and GerontologyInternal medicinemedicineHumansDoxorubicinOlaratumabSoft tissue sarcomaHematologybiologybusiness.industryAntibodies MonoclonalCancerSoft tissueSarcomaHematologySoft tissue sarcomasmedicine.disease030104 developmental biologyOncologyDoxorubicin030220 oncology & carcinogenesisbiology.proteinGeriatrics and GerontologybusinessPlatelet-derived growth factor receptormedicine.drugOlaratumab
researchProduct

Sensitivity and specificity of a commercial ELISA test for anti-MAG antibodies in patients with neuropathy

2020

For the diagnosis of anti-MAG polyneuropathy the commercial ELISA manufacturer currently recommends a cut-off of 1000 Bühlmann Titer Units (BTU). We analyzed sera from 80 anti-MAG neuropathy patients and 383 controls (with other neuropathies or healthy controls) to assess the ELISA sensitivity and specificity at different thresholds. A better combination of sensitivity/specificity was found at a threshold >1500 BTU than at >1000 BTU. The best value of specificity was obtained at threshold >7000 BTU. There was a diagnostic grey area between 1500 and 7000 BTU in which the clinical phenotypes as well as electrophysiological studies need to be carefully assessed particularly to differe…

0301 basic medicinemedicine.medical_specialtyanti-MAG polyneuropathy; chronic inflammatory demyelinating polyradiculoneuropathy; ELISA; sensitivity; specificity; autoantibodies; case-control studies; enzyme-linked immunosorbent assay; humans; myelin-associated glycoprotein; polyneuropathies; retrospective studiesImmunologyAnti-MAG polyneuropathyEnzyme-Linked Immunosorbent AssaySettore MED/26GastroenterologyPolyneuropathies03 medical and health sciencesSensitivity0302 clinical medicineInternal medicinemedicineHumansImmunology and AllergyIn patientAutoantibodiesRetrospective Studieschronic inflammatory demyelinating polyradiculoneuropathyAnti-MAG polyneuropathy chronic inflammatory demyelinating polyradiculoneuropathybiologybusiness.industryAnti magAnti-MAG polyneuropathy chronic inflammatory demyelinating polyradiculoneuropathy; ELISA; Sensitivity; Specificitymedicine.diseaseAutoantibodieMyelin-Associated GlycoproteinTiter030104 developmental biologyPolyneuropathienervous systemNeurologyCase-Control StudiesElisa testSpecificitybiology.proteinELISANeurology (clinical)AntibodyCase-Control StudiebusinessSensitivity (electronics)Polyneuropathy030217 neurology & neurosurgeryHumanJournal of Neuroimmunology
researchProduct

Interleukin-25-mediated resistance against intestinal trematodes does not depend on the generation of Th2 responses

2020

AbstractInterleukin-25 (IL-25) is recognized as the most relevant initiator of protective Th2 responses in intestinal helminth infections. It is well known that IL-25 induces resistance against several species of intestinal helminths, including the trematode Echinostoma caproni. E. caproni has been extensively used as an experimental model to study the factors determining the resistance to intestinal infections. Herein, we assessed the role of IL-25 in the generation of resistance in mice to E. caproni infections. ICR mice are permissive hosts for E. caproni in which chronic infections are developed in relation to the lack of IL-25 production in response to primary infection and the consequ…

0301 basic medicinemedicine.medical_treatmentResistanceDrug ResistanceHelminthiasisGene ExpressionEchinostoma caproniMiceTh20302 clinical medicineEchinostomaInterleukin 25Intestinal Diseases ParasiticSTAT6EchinostomiasisInterleukin-17PhenotypeIntestinesInfectious DiseasesCytokineCytokinesTrematodaSecondary infection030231 tropical medicineAntibodies HelminthTrematode InfectionsBiologyIntestinal helminthlcsh:Infectious and parasitic diseases03 medical and health sciencesTh2 CellsImmune systemMemory cellImmunitymedicineHelminthsAnimalslcsh:RC109-216RNA MessengerPermissiveResistance (ecology)ResearchImmunityDisease Models Animal030104 developmental biologyImmunoglobulin GImmunologySTAT proteinParasitologySTAT6 Transcription FactorInterleuquin-25
researchProduct

Autoantibodies in Spondyloarthritis, Focusing on Anti-CD74 Antibodies

2019

Spondyloarthritis (SpA) is an inflammatory rheumatic disease with diverse clinical presentation. The diagnosis of SpA remains a big challenge in daily clinical practice because of the limitation in specific biomarkers of SpA, more biomarkers are still needed for SpA diagnosis and disease activity monitoring. In the past, SpA was considered predominantly as auto-inflammatory disease vs. autoimmune disease. However, in recent years several researches demonstrated a broad autoantibody response in SpA patients. Study also indicated that mice lack of ZAP70 in T cell develop SpA featured inflammation. These studies indicated the autoimmune features of SpA and gave rise to the potential use of aut…

0301 basic medicinemusculoskeletal diseaseslcsh:Immunologic diseases. AllergyCD74autoantibodiesdiagnosisImmunologyAutoimmunityDiseaseAutoantigensAutoimmune DiseasesPathogenesis03 medical and health sciences0302 clinical medicineHypothesis and TheorySpondylarthritismedicineImmunology and AllergyHumansHeat-Shock ProteinsAutoimmune diseasebiologybusiness.industryChinese patientsAutoantibodyHistocompatibility Antigens Class IIspondyloarthritismedicine.diseaseClinical PracticeAntigens Differentiation B-LymphocyteProtein Phosphatase 2Cstomatognathic diseases030104 developmental biology14-3-3 ProteinsROC CurveImmunologybiology.proteinBiomarker (medicine)Antibodybusinessbeta 2-Microglobulinlcsh:RC581-607Biomarkers030215 immunologyanti-CD74 autoantibodyFrontiers in Immunology
researchProduct

The F4/AS01B HIV-1 Vaccine Candidate Is Safe and Immunogenic, But Does Not Show Viral Efficacy in Antiretroviral Therapy-Naive, HIV-1-Infected Adults…

2016

Supplemental Digital Content is available in the text

0301 basic medicinemyalgiaAdultCD4-Positive T-LymphocytesMalemedicine.medical_specialty4850AdolescentMedizinHIV InfectionsVacunesPlaceboAntibodies Virallaw.invention03 medical and health sciencesYoung Adult0302 clinical medicineRandomized controlled triallawInternal medicineVIH (Virus)medicineHumansSingle-Blind Method030212 general & internal medicineYoung adultAdverse effectAIDS VaccinesVaccinesHIV (Viruses)business.industryClinical Trial/Experimental StudyGeneral MedicineConfidence intervalCD4 Lymphocyte CountClinical trial030104 developmental biologyAnti-Retroviral AgentsImmunologyAntibody FormationComputingMethodologies_DOCUMENTANDTEXTPROCESSINGHIV-1Femalemedicine.symptombusinessViral loadResearch Article
researchProduct